当前位置: X-MOL 学术Antivir. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Chronic hepatitis E in a heart transplant patient: sofosbuvir and ribavirin regimen not fully effective.
Antiviral Therapy ( IF 1.3 ) Pub Date : 2018-3-6 , DOI: 10.3851/imp3227
Eve Todesco 1, 2 , Alessandra Mazzola 3 , Sepideh Akhavan 2, 4 , Florence Abravanel 5, 6 , Thierry Poynard 7 , Anne-Marie Roque-Afonso 8 , Gilles Peytavin 9, 10 , Anne-Geneviève Marcelin 1, 2 , Yvon Calmus 3 , Lucien Lecuyer 11 , Romain Guillemain 12 , Filomena Conti 3
Affiliation  

Hepatitis E virus (HEV) can induce chronic infections in the case of immunosuppression, which are sometimes not cured with ribavirin. Furthermore, sofosbuvir is a highly potent inhibitor of HCV polymerase and was shown to inhibit HEV genotype-3 replication in vitro. We report here the outcome of sofosbuvir/ribavirin therapy on a chronic HEV infection in a heart transplant recipient non-responder to ribavirin. After 24 weeks, the regimen failed to cure the persistent HEV infection, highlighting the need of therapeutic options for HEV-infected immunosuppressed patients.

中文翻译:

心脏移植患者的慢性戊型肝炎:索非布韦和利巴韦林治疗方案无效。

在免疫抑制的情况下,戊型肝炎病毒(HEV)可以诱导慢性感染,有时不能用利巴韦林治愈。此外,sofosbuvir是HCV聚合酶的高效抑制剂,并显示在体外抑制HEV基因型3的复制。我们在这里报告索非布韦/利巴韦林疗法对心脏移植受者无应答的慢性HEV感染的结果。24周后,该方案未能治愈持续性的HEV感染,这凸显出需要针对HEV感染的免疫抑制患者的治疗选择。
更新日期:2020-08-21
down
wechat
bug